Efficacy of atypical v.typical antipsychotics in the treatment of early psychosis: meta-analysis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: There is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis. Aims: To examine the evidence base for this recommendation. Method: Meta-analyses of randomised controlled trials in the early phase of psychosis, looking at long-term discontinuation rates, short-term symptom changes, weight gain and extrapyramidal side-effects. Trials were identified using a combination of electronic (Cochrane Central, EMBASE, MEDLINE and PsycINFO) and manual searches. Results: Fifteen randomised controlled trials with a total of 2522 participants were included. No significant differences between atypical and typical drugs were found for discontinuation rates (odds ratio (OR) = 0.7, 95% CI 0.4 to 1.2) or effect on symptoms (standardised mean difference (SMD) = –0.1, 95% CI –0.2 to 0.02). Participants on atypical antipsychotics gained 2.1 kg (95% CI 0.1 to 4.1) more weight than those on typicals, whereas those on typicals experienced more extrapyramidal side-effects (SMD = –0.4, 95% CI –0.5 to –0.2). Conclusions: There was no evidence for differences in efficacy between atypical and typical antipsychotics, but there was a clear difference in the side-effect profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Leucht, S., & Engel, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300873 · Cited by 154
Cited by
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Zhang, J.-P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 336
Guidelines for the Pharmacotherapy of Schizophrenia in Adults
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720448 · Cited by 332
“In meta-analyses specific to early or first-episode schizophrenia, one reported no differences between antipsychotic class in terms of efficacy or discontinuation rates but clear side effect differences.(18) A more recent meta-analysis reported that SGAs were superior to FGAs in terms of all-cause discontinuation rate…”
ResultMitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
“…recognized that most antipsychotic agents are closely linked with adverse effects on weight, lipids and glucose metabolism and cardiovascular disease (Jin et al. 2004 ; Meyer & Koro, 2004 ; Newcomer, 2005 ; Oriot et al. 2008 ; Smith et al. 2008 ; Yood et al. 2009 ; Crossley et al. 2010).”
BackgroundSecond-Generation Antipsychotics and Extrapyramidal Adverse Effects
Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014) · BioMed Research International · doi:10.1155/2014/656370 · Cited by 327
Cultures for mental health care of young people: an Australian blueprint for reform
McGorry, P. D., Goldstone, S. D., Parker, A. G., Rickwood, D. J., & Hickie, I. B. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00082-0 · Cited by 221
Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
Stevens, G. L., Dawson, G., & Zummo, J. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12278 · Cited by 109
How do people experience early intervention services for psychosis? A meta-synthesis.
Hansen, H., Stige, S. H., Davidson, L., Moltu, C., & Veseth, M. (2018) · Qualitative Health Research · doi:10.1177/1049732317735080 · Cited by 49
Metadata
- Authors
- Crossley, N. A., Constante, M., McGuire, P., & Power, P.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2010-06
- Volume
- 196
- Issue
- 6
- Pages
- 434-439
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2161045715
- Cited by
- 150
- References
- 4
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.